Biotech & Bioprocessing

EU Proposes New Policies to Tackle Chronic Medicine Shortages
Biotech & Bioprocessing EU Proposes New Policies to Tackle Chronic Medicine Shortages

The silent struggle within European pharmacies has reached a tipping point where the simple act of filling a basic prescription for antibiotics or painkillers has become a logistical marathon for healthcare providers and a source of deep anxiety for patients. For too long, the stability of the

Can Antibody Engineering Finally Defeat Glioblastoma?
Biotech & Bioprocessing Can Antibody Engineering Finally Defeat Glioblastoma?

The relentless progression of oncology over the past several decades has fundamentally altered the prognosis for many once-terminal cancers, yet glioblastoma remains a stubborn outlier in this narrative of medical triumph. While the integration of immune checkpoint inhibitors and targeted

Lilly Trial Validates Dual Therapy for Psoriasis and Obesity
Biotech & Bioprocessing Lilly Trial Validates Dual Therapy for Psoriasis and Obesity

The long-standing clinical practice of treating chronic inflammatory diseases and metabolic disorders as entirely separate medical concerns is currently undergoing a radical transformation as new research underscores their deep biological interconnectedness. Traditionally, the medical community has

EU Approves GSK’s Twice-Yearly Asthma and Sinus Treatment
Biotech & Bioprocessing EU Approves GSK’s Twice-Yearly Asthma and Sinus Treatment

Managing severe, persistent respiratory conditions often feels like a relentless battle, with frequent treatments and the constant threat of debilitating flare-ups dictating the rhythm of daily life. For millions, conditions like severe asthma and chronic rhinosinusitis with nasal polyps represent

Gazyva Succeeds in Phase III Autoimmune Kidney Disease Trial
Biotech & Bioprocessing Gazyva Succeeds in Phase III Autoimmune Kidney Disease Trial

A groundbreaking Phase III clinical trial has revealed that the therapy Gazyva (obinutuzumab) demonstrates superior efficacy over the current standard-of-care treatment, tacrolimus, for adults grappling with primary membranous nephropathy. The MAJESTY trial’s success represents a significant

VectorY Launches Landmark Trial for Novel ALS Gene Therapy
Biotech & Bioprocessing VectorY Launches Landmark Trial for Novel ALS Gene Therapy

A single rogue protein, present in nearly every person diagnosed with amyotrophic lateral sclerosis, has long been the focus of intense scientific pursuit and a major roadblock to effective treatment. Netherlands-based biotechnology company VectorY Therapeutics has now initiated a landmark clinical

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later